The introduction of biologic therapies for severe asthma has transformed clinical practice. Among these agents, benralizumab ...
Benralizumab injections reduce exacerbations in severe, uncontrolled asthma, according to two trials
A year's course of benralizumab injections has led to a significant decrease in the frequency of asthma exacerbations -- cutting the rate of exacerbations by a third to a half compared with placebo ...
Learn everything you need to know about Benralizumab-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, ...
Please provide your email address to receive an email when new articles are posted on . The interleukin-5 inhibitor benralizumab yielded durable remission rates in EGPA. The drug showed no new safety ...
The approval of benralizumab (Fasenra) is supported by evidence from the phase 3 TATE study. The FDA has approved benralizumab (Fasenra) for children aged 6 to 11 years with severe eosinophilic asthma ...
Use of benralizumab led to significant improvements in CT mucus scores and asthma control over 2.5 years, as indicated by data from 29 individuals with eosinophilic asthma. "Mucus-plug formation in ...
Benralizumab, an interleukin-5 (IL-5) antagonist used to treat severe asthma, does not weaken antibody response of influenza vaccinations, according to results of a recent study. Benralizumab, an ...
The appraisal committee considered evidence submitted by AstraZeneca and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the evidence.
Review the side-effects of Benralizumab as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of ...
Benralizumab can be used for the treatment of acute eosinophilic exacerbations of asthma and chronic obstructive pulmonary disease (COPD), according to a study published online Nov. 27 in The Lancet ...
Benralizumab injections reduce exacerbations in severe, uncontrolled asthma, according to two trials
A year's course of benralizumab injections has led to a significant decrease in the frequency of asthma exacerbations - cutting the rate of exacerbations by a third to a half compared with placebo ...
The appraisal committee considered evidence submitted by AstraZeneca and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the evidence.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results